The Role and Rationale for Oral Options in the Treatment of Metastatic Breast Cancer

The Role and Rationale for Oral Options in the Treatment of Metastatic Breast Cancer

Episodes

Specialty:

All

Year:

All

EP. 1: Treatment Advances in Metastatic Breast Cancer

ByAdam M. Brufsky, MD, PhD, University of Pittsburgh/UPMC Hillman Cancer Center,Lee S. Schwartzberg, MD, FACP, West Cancer Center & Research Institute,George W. Sledge Jr., MD, Stanford Cancer Center

January 19th 2021

EP. 2: Long-Term Disease Control in Metastatic Breast Cancer

ByAdam M. Brufsky, MD, PhD, University of Pittsburgh/UPMC Hillman Cancer Center,Lee S. Schwartzberg, MD, FACP, West Cancer Center & Research Institute,George W. Sledge Jr., MD, Stanford Cancer Center

January 19th 2021

EP. 3: Cytotoxic Chemotherapy for Metastatic Breast Cancer

ByAdam M. Brufsky, MD, PhD, University of Pittsburgh/UPMC Hillman Cancer Center,Lee S. Schwartzberg, MD, FACP, West Cancer Center & Research Institute,George W. Sledge Jr., MD, Stanford Cancer Center

January 19th 2021

EP. 4: Assessing Response to Chemotherapy in Metastatic Breast Cancer

ByAdam M. Brufsky, MD, PhD, University of Pittsburgh/UPMC Hillman Cancer Center,Lee S. Schwartzberg, MD, FACP, West Cancer Center & Research Institute,George W. Sledge Jr., MD, Stanford Cancer Center

January 19th 2021

EP. 5: Metastatic Breast Cancer: Chemotherapy Selection

ByAdam M. Brufsky, MD, PhD, University of Pittsburgh/UPMC Hillman Cancer Center,Lee S. Schwartzberg, MD, FACP, West Cancer Center & Research Institute,George W. Sledge Jr., MD, Stanford Cancer Center

January 26th 2021

EP. 6: Predicting Response to Chemotherapy in Metastatic Breast Cancer

ByAdam M. Brufsky, MD, PhD, University of Pittsburgh/UPMC Hillman Cancer Center,Lee S. Schwartzberg, MD, FACP, West Cancer Center & Research Institute,George W. Sledge Jr., MD, Stanford Cancer Center

January 26th 2021

EP. 7: Chemotherapy to Treat MBC: Drug Developments

ByAdam M. Brufsky, MD, PhD, University of Pittsburgh/UPMC Hillman Cancer Center,Lee S. Schwartzberg, MD, FACP, West Cancer Center & Research Institute,George W. Sledge Jr., MD, Stanford Cancer Center

February 2nd 2021

EP. 8: Advantages of Oral Therapy for Metastatic Breast Cancer

ByAdam M. Brufsky, MD, PhD, University of Pittsburgh/UPMC Hillman Cancer Center,Lee S. Schwartzberg, MD, FACP, West Cancer Center & Research Institute,George W. Sledge Jr., MD, Stanford Cancer Center

February 2nd 2021

EP. 9: At-Home Administration of Therapies to Treat MBC

ByAdam M. Brufsky, MD, PhD, University of Pittsburgh/UPMC Hillman Cancer Center,Lee S. Schwartzberg, MD, FACP, West Cancer Center & Research Institute,George W. Sledge Jr., MD, Stanford Cancer Center

February 9th 2021

EP. 10: Metastatic Breast Cancer Therapy: OPE

ByAdam M. Brufsky, MD, PhD, University of Pittsburgh/UPMC Hillman Cancer Center,Lee S. Schwartzberg, MD, FACP, West Cancer Center & Research Institute,George W. Sledge Jr., MD, Stanford Cancer Center

February 9th 2021

EP. 11: MBC Therapy: Tesetaxel/Capecitabine

ByAdam M. Brufsky, MD, PhD, University of Pittsburgh/UPMC Hillman Cancer Center,Lee S. Schwartzberg, MD, FACP, West Cancer Center & Research Institute,George W. Sledge Jr., MD, Stanford Cancer Center

February 16th 2021

EP. 12: Oral Therapies and Dose Reductions in MBC

ByAdam M. Brufsky, MD, PhD, University of Pittsburgh/UPMC Hillman Cancer Center,Lee S. Schwartzberg, MD, FACP, West Cancer Center & Research Institute,George W. Sledge Jr., MD, Stanford Cancer Center

February 16th 2021

EP. 13: Using Oral Therapies to Advance Care in MBC

ByAdam M. Brufsky, MD, PhD, University of Pittsburgh/UPMC Hillman Cancer Center,Lee S. Schwartzberg, MD, FACP, West Cancer Center & Research Institute,George W. Sledge Jr., MD, Stanford Cancer Center

February 16th 2021

Trending on OncLive

FDA Approves Imlunestrant Plus Abemaciclib for ER+, HER2–, ESR1-Mutated Metastatic Breast Cancer

The OncFive: Top Oncology Articles for the Week of 9/14/2026

Zipalertinib + Chemotherapy Extends PFS by 6 Months in Frontline EGFR Exon 20 Insertion–Positive NSCLC

Five Under 5: Top Oncology Videos for the Week of 9/13

Updated NCCN Guidelines Feature Additional MRD Recommendations in Multiple Myeloma